Subject engraftment with a singly applied NB01 using proprietary qPCR assays that detect the relative percentages of health-associated (NB01) and disease-associated bacteria to total bacteria recovered.

Dose schedule determination based on the duration of engraftment of a singly applied NB01

Safety profile and tolerability of a singly applied NB01 using the Investigator Global Assessment (IGA) 5-Point Score, with higher scores representing worsening or more severe acne

Proportion of Patients With Success According to the Dichotomized IGA Scale Based on Facial Assessments 12 Weeks After the First Treatment. Success is Defined as an Improvement of at Least 2 Grades From the Baseline Score.